Medicinal Chemistry of Pyrazolopyrimidine Scaffolds Substituted with Different Heterocyclic Nuclei

激酶 细胞周期蛋白依赖激酶 化学 药物发现 生物化学 生物 药理学 细胞周期 细胞
作者
Galal H. Elgemeie,Rasha A. Azzam,Wafaa A. Zaghary,Mohammed A. Khedr,Gihad E. Elsherif
出处
期刊:Current Pharmaceutical Design [Bentham Science Publishers]
卷期号:28 (41): 3374-3403 被引量:6
标识
DOI:10.2174/1381612829666221102162000
摘要

Background: Medicinal chemistry of pyrazolopyrimidine scaffolds substituted with different heterocyclic nuclei has attracted great attention due to their wide range of biological activities that have been reported. Pyrazolopyrimidine scaffold is an important privileged heterocycle nucleus in drug discovery. Methods: All pharmacological activities of pyrazolopyrimidine scaffold have been mentioned, such as anticancer, anti-inflammatory, antihypertensive, antitubercular, antiviral, antibacterial, antifungal, antidiabetic, and anti-obesity agents. In addition, it was used in both osteoporosis and neurological disorders. The difference in potency and bioavailability of pyrazolopyrimidine derivatives refers to the substituent groups that can increase the activity against specific targets and enhance their selectivity. Results: This review provides an overview of different synthetic pathways, structure activity relationships, and preclinical studies of pyrazolopyrimidine scaffolds substituted with a variety of heterocyclic nuclei, as well as it provides a discussion on the significant biological findings of these important scaffolds. In addition, it provides some insights on the different macromolecular targets that pyrazolopyrimidine scaffold can effectively work on, such as; cyclin dependent kinases; CDK2, CDK7, and CDK9, checkpoint kinases; CHK1 and CHK2 and their correlation with the anticancer activity, PI3Kα, transient receptor potential canonical 6, B-Raf kinase, Interleukin- 1 receptor-associated kinase 4, B-cell lymphoma 6, TRKA-C kinase, potent kDa ribosomal protein S6 kinase, colon cancer cell line (CaCo-2), domain receptor kinase (KDR), HepG-2 carcinoma cell, FLT3. The antibacterial activity against B. subtilis and E. coli and antifungal activity against C. albicans, C. tropicalis, A. niger, and A. clavatus are discussed. Conclusion: This review provides an overview of the different pharmacological activities of the pyrazolopyrimidine scaffold and its correlation with chemical structure. Some exciting new developments in pyrazolopyrimidine scaffolds are also presented in this review.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
CodeCraft应助科研通管家采纳,获得10
刚刚
我是老大应助科研通管家采纳,获得10
刚刚
华仔应助科研通管家采纳,获得10
刚刚
刚刚
上官若男应助科研通管家采纳,获得10
刚刚
Jasper应助科研通管家采纳,获得10
1秒前
大个应助科研通管家采纳,获得10
1秒前
科研通AI5应助科研通管家采纳,获得10
1秒前
blUe完成签到,获得积分10
1秒前
搜集达人应助科研通管家采纳,获得10
1秒前
科研通AI2S应助科研通管家采纳,获得10
1秒前
优秀的映萱完成签到,获得积分10
1秒前
Hello应助科研通管家采纳,获得30
1秒前
1秒前
1秒前
nico发布了新的文献求助10
1秒前
2秒前
ref:rain完成签到,获得积分10
2秒前
盒子盒子完成签到 ,获得积分10
3秒前
3秒前
开心的我完成签到,获得积分10
3秒前
3秒前
叨叨小夫夫完成签到,获得积分10
3秒前
jerry完成签到,获得积分10
3秒前
hh完成签到,获得积分10
4秒前
十一完成签到,获得积分10
4秒前
求学发布了新的文献求助10
4秒前
负责的凌波应助zhenglei9058采纳,获得10
4秒前
burn发布了新的文献求助10
4秒前
Zhangqiang完成签到,获得积分10
4秒前
wanghuu完成签到,获得积分10
5秒前
wangjue发布了新的文献求助10
5秒前
君临完成签到,获得积分10
6秒前
zhukun完成签到,获得积分10
6秒前
Endless完成签到,获得积分10
6秒前
wannna发布了新的文献求助10
6秒前
量子星尘发布了新的文献求助10
6秒前
今天别生气完成签到,获得积分10
6秒前
烟花应助北雁采纳,获得10
6秒前
学术疯子发布了新的文献求助10
6秒前
高分求助中
Comprehensive Toxicology Fourth Edition 24000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
TOWARD A HISTORY OF THE PALEOZOIC ASTEROIDEA (ECHINODERMATA) 1000
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
World Nuclear Fuel Report: Global Scenarios for Demand and Supply Availability 2025-2040 800
The Social Work Ethics Casebook(2nd,Frederic G. R) 600
Handbook of Social and Emotional Learning 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5118645
求助须知:如何正确求助?哪些是违规求助? 4324517
关于积分的说明 13472791
捐赠科研通 4157640
什么是DOI,文献DOI怎么找? 2278510
邀请新用户注册赠送积分活动 1280244
关于科研通互助平台的介绍 1219029